Your browser is no longer supported. Please, upgrade your browser.
AZN [NASD]
AstraZeneca PLC
Index- P/E38.51 EPS (ttm)1.51 Insider Own0.50% Shs Outstand2.62B Perf Week2.54%
Market Cap179.66B Forward P/E13.49 EPS next Y4.32 Insider Trans0.00% Shs Float2.61B Perf Month0.43%
Income3.98B PEG2.03 EPS next Q0.43 Inst Own16.80% Short Float5.24% Perf Quarter11.42%
Sales27.58B P/S6.51 EPS this Y137.20% Inst Trans0.40% Short Ratio13.28 Perf Half Y9.35%
Book/sh5.50 P/B10.59 EPS next Y27.93% ROA6.20% Target Price63.60 Perf Year5.55%
Cash/sh2.52 P/C23.14 EPS next 5Y19.00% ROE29.20% 52W Range46.48 - 60.93 Perf YTD16.48%
Dividend1.40 P/FCF91.85 EPS past 5Y1.70% ROI12.20% 52W High-4.43% Beta0.55
Dividend %2.40% Quick Ratio0.70 Sales past 5Y1.50% Gross Margin79.00% 52W Low25.28% ATR0.94
Employees76100 Current Ratio0.90 Sales Q/Q15.20% Oper. Margin21.20% RSI (14)49.25 Volatility1.35% 1.32%
OptionableYes Debt/Eq1.40 EPS Q/Q99.20% Profit Margin14.40% Rel Volume1.37 Prev Close57.96
ShortableYes LT Debt/Eq1.24 EarningsJul 29 BMO Payout90.40% Avg Volume10.31M Price58.23
Recom1.50 SMA20-1.47% SMA500.58% SMA2009.53% Volume14,081,008 Change0.47%
Apr-12-21Downgrade Argus Buy → Hold
Mar-16-21Upgrade Jefferies Hold → Buy
Feb-25-21Upgrade UBS Neutral → Buy
Jan-15-21Initiated Deutsche Bank Buy
Dec-07-20Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-30-20Upgrade UBS Sell → Neutral
Nov-11-20Upgrade HSBC Securities Reduce → Hold
Sep-29-20Initiated Berenberg Buy
Nov-22-19Initiated SVB Leerink Outperform
Oct-25-19Upgrade Liberum Hold → Buy
Apr-02-19Downgrade UBS Neutral → Sell
Feb-05-19Initiated Exane BNP Paribas Outperform
Jan-25-19Upgrade Shore Capital Hold → Buy
Dec-11-18Resumed Jefferies Hold
Oct-09-18Initiated Guggenheim Buy
Aug-16-18Downgrade Jefferies Buy → Hold
Mar-19-18Upgrade Jefferies Hold → Buy
Feb-06-18Reiterated Leerink Partners Mkt Perform $36 → $38
Feb-05-18Reiterated Bernstein Outperform $40 → $42
Jan-18-18Reiterated Leerink Partners Mkt Perform $33 → $36
Jul-25-21 06:20PM  
Jul-24-21 02:36AM  
Jul-23-21 03:12PM  
01:53PM  
07:30AM  
07:00AM  
Jul-22-21 08:22PM  
04:25PM  
02:36PM  
10:16AM  
05:52AM  
Jul-21-21 05:00PM  
02:14PM  
01:43PM  
10:39AM  
06:10AM  
Jul-20-21 02:51PM  
02:06PM  
06:00AM  
04:50AM  
Jul-19-21 02:01PM  
11:24AM  
08:45AM  
08:30AM  
Jul-18-21 11:46AM  
Jul-17-21 07:01AM  
06:48AM  
Jul-16-21 01:37PM  
12:29PM  
11:52AM  
10:17AM  
10:09AM  
09:48AM  
08:12AM  
07:57AM  
07:18AM  
07:11AM  
06:46AM  
06:20AM  
02:01AM  
Jul-15-21 07:27PM  
07:01PM  
05:00PM  
02:58PM  
01:50PM  
07:49AM  
Jul-14-21 06:16PM  
02:14PM  
01:49PM  
09:45AM  
06:33AM  
06:31AM  
03:04AM  
02:55AM  
02:26AM  
Jul-13-21 01:39PM  
01:04PM  
01:03PM  
09:52AM  
09:42AM  
07:42AM  
07:06AM  
06:50AM  
06:43AM  
06:18AM  
05:08AM  
05:06AM  
02:00AM  
Jul-12-21 05:28PM  
03:09PM  
07:11AM  
04:04AM  
Jul-11-21 10:03PM  
Jul-10-21 06:35AM  
Jul-09-21 02:34PM  
02:22PM  
11:02AM  
10:55AM  
09:12AM  
09:00AM  
08:28AM  
08:28AM  
08:10AM  
07:39AM  
05:51AM  
04:39AM  
12:41AM  
Jul-08-21 04:49PM  
01:57PM  
01:26PM  
11:53AM  
10:11AM  
09:23AM  
08:00AM  
07:01AM  
07:00AM  
06:51AM  
06:00AM  
04:15AM  
03:04AM  
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.